Clinical trial
A Randomized, Phase 3, Open-label Study to Investigate Pharmacokinetics, Safety, and Efficacy of Subcutaneous Compared to Intravenous Frexalimab in Adult Participants With Multiple Sclerosis
NCT07325292 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Phase 3, Open-label Study to Investigate Pharmacokinetics, Safety, and Efficacy of Subcutaneous Compared to Intravenous Frexalimab in Adult Participants With Multiple Sclerosis
- Lead sponsor
- Sanofi
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- January 14, 2026
- Completion date
- November 30, 2028
- Enrollment
- 160 (estimated)
- Sites
- 68
Conditions
As the registry lists them; a condition with its own page is linked.